Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2
Subject: Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA1/TA2Solicitation Number: DARPA-PS-26-124Notice Type: SOLICITNAICS: 541714Notice Published: 05-27-26Response Due: 06-24-26Agency: DEPT OF DEFENSEOffice: DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)Contact: BAA Coordinator This email address is being protected from spambots. You need JavaScript enabled to view it.Office Address: ARLINGTON, VA 222032114Related Notices:
Click for official SAM (FBO) notice, additional information, and accompanying attachments
The Resuscitation and Prevention of Ischemia-induced Dysfunction (RAPIID) program seeks to deliver a transformative, end-to-end resuscitation system that redefines far-forward trauma care. RAPIID aims for this system to be fieldable, usable, and scalable, providing a capability equivalent or superior to stored whole blood in early resuscitation while removing dependence on cold chain and donor logistics. RAPIID seeks to do this by developing a blood analog system (BAS) comprising sequentially administered blood analog components, integrated with ruggedized delivery formats, point-of-care diagnostics, and clinical practice guidelines (CPGs). To maximize post-program viability of developed products, RAPIID will develop and execute effective regulatory and commercialization strategies and accelerate advanced development through technology readiness level (TRL) 7 (Scale-up and Phase II Clinical Trials)1 for blood analog components and TRL 8 (Clinical Studies)2 for devices and diagnostics. This solicitation is to request proposals addressing ONLY Phase 1 of Task Area (TA)-1 and/or TA-2.